Repligen (RGEN) Competitors $144.46 -2.08 (-1.42%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RGEN vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, MDGL, and HALOShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Repligen vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do insiders & institutionals have more ownership in ALNY or RGEN? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to ALNY or RGEN? In the previous week, Repligen had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for Repligen and 13 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.62 beat Repligen's score of 0.62 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 6 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ALNY or RGEN more profitable? Repligen has a net margin of -3.36% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Repligen's return on equity of 3.90% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% Repligen -3.36%3.90%2.72% Do analysts rate ALNY or RGEN? Alnylam Pharmaceuticals currently has a consensus target price of $298.09, suggesting a potential upside of 21.45%. Repligen has a consensus target price of $185.20, suggesting a potential upside of 28.20%. Given Repligen's higher probable upside, analysts plainly believe Repligen is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71Repligen 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62 Which has more risk & volatility, ALNY or RGEN? Alnylam Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Does the MarketBeat Community prefer ALNY or RGEN? Alnylam Pharmaceuticals received 725 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.60% of users gave Repligen an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113476.16% Underperform Votes35523.84% RepligenOutperform Votes40967.60% Underperform Votes19632.40% Which has higher earnings and valuation, ALNY or RGEN? Repligen has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.09B15.11-$440.24M-$2.62-93.68Repligen$639.92M12.65$35.60M-$0.37-390.43 SummaryAlnylam Pharmaceuticals and Repligen tied by winning 9 of the 18 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.09B$2.94B$5.07B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-390.4245.9499.0517.15Price / Sales12.65411.851,121.17116.80Price / Cash51.55182.1041.5237.88Price / Book4.113.894.754.78Net Income$35.60M-$42.21M$119.33M$225.60M7 Day Performance-7.64%-2.14%-1.86%-1.23%1 Month Performance2.17%4.21%11.40%3.07%1 Year Performance-20.67%18.39%30.26%16.48% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.0971 of 5 stars$144.46-1.4%$185.20+28.2%-19.7%$8.09B$639.92M-390.421,783Analyst ForecastPositive NewsHigh Trading VolumeALNYAlnylam Pharmaceuticals4.4124 of 5 stars$246.53+0.4%$298.09+20.9%+37.1%$31.80B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6223 of 5 stars$151.25+0.8%$245.32+62.2%-41.0%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7138 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8249 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7042 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9838 of 5 stars$66.07+0.1%$94.20+42.6%-29.1%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.4854 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600EXELExelixis4.5077 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RGEN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts